loading...| Preferred Name |
Sorafenib |
|
| Synonyms |
BAY 43-9006 |
|
| Definitions |
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. |
|
| ID |
http://purl.bioontology.org/ontology/MESH/D000077157 |
|
| altLabel |
BAY 43-9006 Nexavar BAY 545 9085 BAY 43 9006 Sorafenib Tosylate BAY-545-9085 BAY 5459085 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl- Sorafenib N-Oxide 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate BAY 673472 BAY 439006 BAY 545-9085 BAY-673472 BAY5459085 Sorafenib N Oxide |
|
| AQL |
AA AD AE AG AI AN BL CF CH CL CS EC HI IM IP ME PD PK PO RE SD ST TO TU UR |
|
| cui |
C2713536 C1174389 C4704722 C1676709 C1677799 C4551885 C1516119 |
|
| DC |
1 |
|
| definition |
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. |
|
| DX |
20190101 |
|
| HN |
2019 (2003) |
|
| Inverse of AQ |
http://purl.bioontology.org/ontology/MESH/Q000097 http://purl.bioontology.org/ontology/MESH/Q000627 http://purl.bioontology.org/ontology/MESH/Q000493 http://purl.bioontology.org/ontology/MESH/Q000494 http://purl.bioontology.org/ontology/MESH/Q000276 http://purl.bioontology.org/ontology/MESH/Q000138 http://purl.bioontology.org/ontology/MESH/Q000134 http://purl.bioontology.org/ontology/MESH/Q000266 http://purl.bioontology.org/ontology/MESH/Q000378 http://purl.bioontology.org/ontology/MESH/Q000008 http://purl.bioontology.org/ontology/MESH/Q000009 http://purl.bioontology.org/ontology/MESH/Q000031 http://purl.bioontology.org/ontology/MESH/Q000032 http://purl.bioontology.org/ontology/MESH/Q000037 http://purl.bioontology.org/ontology/MESH/Q000191 http://purl.bioontology.org/ontology/MESH/Q000302 http://purl.bioontology.org/ontology/MESH/Q000145 http://purl.bioontology.org/ontology/MESH/Q000592 http://purl.bioontology.org/ontology/MESH/Q000737 http://purl.bioontology.org/ontology/MESH/Q000819 http://purl.bioontology.org/ontology/MESH/Q000506 http://purl.bioontology.org/ontology/MESH/Q000633 http://purl.bioontology.org/ontology/MESH/Q000600 |
|
| Inverse of RB |
5XYK65KIGD 9ZOQ3TZI87 5T62Q3B36J 0 |
|
| isa | ||
| LT |
TRD |
|
| Machine permutation |
2019; SORAFENIB was indexed under NIACINAMIDE and PHENYLUREA COMPOUNDS 2014-2018, and under BENZENESULFONATES and PYRIDINES 2003-2013 |
|
| MDA |
20180709 |
|
| MMR |
20200527 |
|
| MN |
D02.455.426.559.389.703.757 D02.065.950.681.757 D03.383.725.547.530.750 D03.066.515.530.750 |
|
| notation |
D000077157 |
|
| PA |
D047428 D000970 |
|
| prefLabel |
Sorafenib |
|
| RR |
5XYK65KIGD 5T62Q3B36J |
|
| TERMUI |
T533756 T000937070 T000937073 T752283 T752284 T000937075 T662665 T000938933 T000937074 |
|
| TH |
NLM (2009) NLM (2005) FDA SRS (2018) NLM (2015) NLM (2019) USAN (19XX) INN (19XX) NLM (2003) FDA SRS (2015) |
|
| tui |
T109 T121 |
|
| subClassOf |